You can fight acne not only with gel or special soaps, but also with natural masks. Masks made of products you easily may find in your kitchen and you easily can make, too. These ones are granted to work. These products have great qualities that are inherent in the most ordinary things that can make you beautiful, cleansing your skin and brightening your complexion.
The mask made of eggs is one of the most common and it is a good method for toning the skin, according to some experts. They say that eggs help tightening your skin, giving you a firmer face, less wrinkled and less prone to sagging.
To make an egg mask is something quite simple and fast that you can not even imagine. First, beat one egg white until it is stiff. After that you just smooth it over your entire face. Then, remove the mask, but after 20 minutes.
You can adjust the mask to your skin type. If your have oily skin, add lemon juice to the egg white (only one drop). And if you have dry skin, put a bit of honey to the egg white. Experts explain that the skin on the inside of the shell can actually work as an acne treatment. Just place the skin over the breakout and leave on for 30 minute or even overnight to help reduce the appearance of the acne.
It is recommended to apply facial masks once a week for best results. Remember rinsing your face first with warm water and then rinsing with cold (to close the pores) after you finish removing the mask.
Showing posts with label acne treatments. Show all posts
Showing posts with label acne treatments. Show all posts
Thursday, March 25, 2010
Sunday, March 14, 2010
Acne: Asthma Drug Fails to Help Patients with Acne
The asthma drug Zyflo fails to help patients with severe acne, according to a mid-stage trial carried out by the company Critical Therapeutics Inc. The drug, also known as zileuton, was neither better at controlling the number of inflammatory lesions than placebos under the company statistics.
Over the 12-week trial, patients treated with Zyflo had an average reduction of 11.5 inflammatory lesions. That compared with a reduction of 9.1 lesions in a group of other patients taking placebos – far short of achieving statistical significance.
Patients treated with placebo showed a reduction of 16.4 lesions in the placebo group, but patients treated with Zyflo showed a mean reduction in the total number of lesions of 25.3.
The company stated the medicine showed a trend of potential benefit to some patients although the drug failed the primary goal of the trial.
Linda Lennox, the company spokeswoman, told the company will probably conduct a larger trial testing the medicine as an acne treatment, using information gleaned from the small recent "proof of concept" trial.
The company based in Lexington, Massachusetts, said that it is continuing to analyze the data and is working with the investigators to further interpret the results.
Zyflo blocks an inflammation-causing enzyme called 5 lipoxygenase (5-LO). It was approved by U.S. regulators in 1996 for treating asthma patients 12 years of age and older. At the time, the drug was owned by Abbott Laboratories Inc., which sold it for a number of years before licensing it to Critical Therapeutics in late 2003.
Over the 12-week trial, patients treated with Zyflo had an average reduction of 11.5 inflammatory lesions. That compared with a reduction of 9.1 lesions in a group of other patients taking placebos – far short of achieving statistical significance.
Patients treated with placebo showed a reduction of 16.4 lesions in the placebo group, but patients treated with Zyflo showed a mean reduction in the total number of lesions of 25.3.
The company stated the medicine showed a trend of potential benefit to some patients although the drug failed the primary goal of the trial.
Linda Lennox, the company spokeswoman, told the company will probably conduct a larger trial testing the medicine as an acne treatment, using information gleaned from the small recent "proof of concept" trial.
The company based in Lexington, Massachusetts, said that it is continuing to analyze the data and is working with the investigators to further interpret the results.
Zyflo blocks an inflammation-causing enzyme called 5 lipoxygenase (5-LO). It was approved by U.S. regulators in 1996 for treating asthma patients 12 years of age and older. At the time, the drug was owned by Abbott Laboratories Inc., which sold it for a number of years before licensing it to Critical Therapeutics in late 2003.
Subscribe to:
Posts (Atom)